Looking to publish in Annals Of The Rheumatic Diseases? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowAnnals of the Rheumatic Diseases is an international peer reviewed rheumatology journal committed to promoting high standards of scientific exchange and education. It publishes original research, reviews, recommendations, viewpoints, and related work spanning clinical, basic, and translational science across inflammatory and non-inflammatory musculoskeletal conditions.
Looking to publish in Annals Of The Rheumatic Diseases? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Annals Of The Rheumatic Diseases accepts the following article types. Click on an article type to view submission instructions.
Original Research
Review
Recommendations And Criteria
Letter
Recent Publications
International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases
Roko P.A. Nikolic, Eldad Ben-Chetrit, Marvin J. Fritzler, Katherine A. Buhler, Arveen Shokravi, Nathan H. Barreth, Edward K.L. Chan, Luís E.C. Andrade, Monica Lin, Jappn Grewal, Jill Buyon, Jan Damoiseaux, Adrian Y.S. Lee, Günter Steiner, Henri A. Ménard, Gilles Boire, Ger J.M. Pruijn, Westley H. Reeves, Minoru Satoh, R.Hal Scofield, Anne E. Tebo, Mark Wener, May Y. Choi
Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis
Kusuma Ananth, Katharine B Moosic, Eduardo Gomez-Banuelos, Hong Wang, Isabel Trejo-Zambrano, Ramona Johnson, Jessica Marie Kirschmann, Tess Deddens, Omar Elghawy, Bryna Shemo, William H Robinson, Donald Kimpel, Clifton O Bingham, David J Feith, Brendan Antiochos, Felipe Andrade, Thomas P Loughran, Erika Darrah
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
Federica Bonaso, Bohang Jiang, Laura J Yockey, Jesse Akaa, Ian Doyle, Evan Hsu, Courtney LeSon, Grace McMahon, Isha Jha, Sydney B Montesi, Guy Katz, Thomas V Guy, Vinay S Mahajan, Shiv Pillai, Pui Lee, John H Stone, Zachary S Wallace, Cory A Perugino
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment
Alexis Ogdie, Philip J. Mease, Emmanouil Rampakakis, Karissa Lozenski, Mohamed Sharaf, Elizabeth Adamson, Helena Marzo-Ortega, Laure Gossec
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial
Edward Vital, Chun Wu, J. Michelle Kahlenberg, Cristina Arriens, Mary K. Crow, Amit Saxena, Ian M. Catlett, Coburn Hobar, Yanhua Hu
Frequently asked questions
How long does it take to publish?
81 days from submission to acceptance.
Reformat to Annals Of The Rheumatic Diseases using Livewrite PremiumWhat are the publication costs?
Open access articles require payment of an article publishing charge (APC) if the manuscript is accepted.
Reformat to Annals Of The Rheumatic Diseases using Livewrite Premium